1.38
+0.2(+16.95%)
Currency In USD
| Previous Close | 1.18 |
| Open | 1.21 |
| Day High | 1.41 |
| Day Low | 1.05 |
| 52-Week High | 2.27 |
| 52-Week Low | 0.4 |
| Volume | 755,341 |
| Average Volume | 925,490 |
| Market Cap | 73.9M |
| PE | -0.69 |
| EPS | -2.01 |
| Moving Average 50 Days | 1.5 |
| Moving Average 200 Days | 0.91 |
| Change | 0.2 |
If you invested $1000 in ALX Oncology Holdings Inc. (ALXO) since IPO date, it would be worth $46 as of November 09, 2025 at a share price of $1.38. Whereas If you bought $1000 worth of ALX Oncology Holdings Inc. (ALXO) shares 3 years ago, it would be worth $111.11 as of November 09, 2025 at a share price of $1.38.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
ALX Oncology to Report Third Quarter 2025 Financial Results and Pipeline Progress Including Evorpacept CD47 Biomarker Data to be Presented at Upcoming SITC Annual Meeting
GlobeNewswire Inc.
Oct 30, 2025 12:30 PM GMT
SOUTH SAN FRANCISCO, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or the "Company") (Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and
ALX Oncology Announces Preclinical Data and Phase 1 Trial-in-Progress Presentations of ALX2004, a Novel EGFR-Targeted ADC, at 2025 AACR-NCI-EORTC Conference
GlobeNewswire Inc.
Oct 23, 2025 4:30 PM GMT
-Two poster presentations showcase best- and first-in-class potential of ALX2004, a novel, antibody-drug conjugate (ADC) for the treatment of EGFR-expressing solid tumors -Robust body of preclinical data supports ALX2004 differentiation in EGFR-ADC c
ALX Oncology to Present Updated Data from Phase 2 ASPEN-06 Trial, Highlighting CD47 Expression as a Predictive Biomarker in HER2+ Gastric Cancer, at 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting
GlobeNewswire Inc.
Oct 03, 2025 1:05 PM GMT
Company will share data demonstrating CD47 overexpression as key predictive biomarker for response with the Company’s lead candidate, evorpacept, in HER2+ gastric cancer SOUTH SAN FRANCISCO, Calif., Oct. 03, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Ho